BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Remsima SC wins approval for additional indications in Europe

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 29, 2020, 12:42 | Updated : June 29, 2020, 12:42
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease, has secured approval from a European watchdog for additional indications, opening the door for global use.

Remicade (Infliximab) biosimilar exist in the form of conventional intravenous injection. The target of Remsima SC is patients who are forced to move on to expensive secondary treatments due to resistance. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject Remsima SC into the fat layer beneath the skin at home.

Celltrion, a leading biosimilar manufacturer in South Korea, said that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for Remsima SC's indications covering Crohn's disease, ulcerative colitis, cataracts, psoriatic arthritis and psoriasis for adults. 

Remsima SC will be the first subcutaneous injection type to obtain all adult indications of Infliximab's intravenous injection type, Celltrion said, adding it would seek approval in 97 countries across the world within this year.

Celltrion said Remsima SC is expected to increase its global presence rapidly because medical staff's preference for infliximab prescription, a component of Remsima SC, is high in the field of inflammatory bowel disease. "Infliximab, the main ingredient of Ramsima SC, is considered the most preferred ingredient by specialists in inflammatory bowel disease, so a remarkable market share is expected in the future," an unnamed Celltrion official said in a statement. "

With Remsima SC, Celltrion has adopted an aggressive strategy to secure profitability and price penetration in competition with other subcutaneous-type products such as Adalimumab sold under the brand name of Humira, which is on the World Health Organization's list of essential medicines.



 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .[Coronavirus] Celltrion selected as priority negotiator in state project to develop treatment.
    [Coronavirus] Celltrion selected as priority negotiator in s…
  • .Celltrion selected for state project to develop pen-type insulin biosimilar.
    Celltrion selected for state project to develop pen-type ins…
  • .Bio firm Celltrion wins domestic approval to sell Remsima SC.
    Bio firm Celltrion wins domestic approval to sell Remsima SC
  • .Celltrion discloses $517 mln investment to build production base in China .
    Celltrion discloses $517 mln investment to build production …

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view